Alex George

List of Publications by Year
in descending order

27 papers	888 citations	687363 13 h-index	677142 22 g-index
27 all docs	27 docs citations	27 times ranked	1382 citing authors

#	Article	IF	Citations
1	Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemiaâ€"TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet, The, 2016, 387, 661-670.	13.7	375
2	Erythrocyte NADPH oxidase activity modulated by Rac GTPases, PKC, and plasma cytokines contributes to oxidative stress in sickle cell disease. Blood, 2013, 121, 2099-2107.	1.4	162
3	The homeobox gene Hex induces T-cell-derived lymphomas when overexpressed in hematopoietic precursor cells. Oncogene, 2003, 22, 6764-6773.	5.9	46
4	Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease. Blood Advances, 2017, 1, 1645-1649.	5.2	38
5	Losartan for the nephropathy of sickle cell anemia: A phaseâ€2, multicenter trial. American Journal of Hematology, 2017, 92, E520-E528.	4.1	36
6	Validation of a Low-Cost Paper-Based Screening Test for Sickle Cell Anemia. PLoS ONE, 2016, 11, e0144901.	2.5	33
7	Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial). Blood Advances, 2018, 2, 1969-1979.	5.2	29
8	A Paper-Based Test for Screening Newborns for Sickle Cell Disease. Scientific Reports, 2017, 7, 45488.	3.3	27
9	Genetic Modifiers of White Blood Cell Count, Albuminuria and Glomerular Filtration Rate in Children with Sickle Cell Anemia. PLoS ONE, 2016, 11, e0164364.	2.5	25
10	Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease. JAMA - Journal of the American Medical Association, 2021, 325, 1513.	7.4	24
11	A rapid paperâ€based test for quantifying sickle hemoglobin in blood samples from patients with sickle cell disease. American Journal of Hematology, 2015, 90, 478-482.	4.1	20
12	TCD with Transfusions Changing to Hydroxyurea (TWiTCH): Hydroxyurea Therapy As an Alternative to Transfusions for Primary Stroke Prevention in Children with Sickle Cell Anemia. Blood, 2015, 126, 3-3.	1.4	19
13	Wholeâ€exome sequencing of sickle cell disease patients with hyperhemolysis syndrome suggests a role for rare variation in disease predisposition. Transfusion, 2018, 58, 726-735.	1.6	17
14	A Multi-Center, Phase-2 Trial of Losartan for the Nephropathy of Sickle Cell Anemia. Blood, 2016, 128, 265-265.	1.4	10
15	Substituting Sodium Hydrosulfite with Sodium Metabisulfite Improves Long-Term Stability of a Distributable Paper-Based Test Kit for Point-of-Care Screening for Sickle Cell Anemia. Biosensors, 2017, 7, 39.	4.7	8
16	Novel dose escalation to predict treatment with hydroxyurea (<scp>NDEPTH</scp>): A randomized controlled trial of a doseâ€prediction equation to determine maximum tolerated dose of hydroxyurea in pediatric sickle cell disease. American Journal of Hematology, 2020, 95, E242-E244.	4.1	5
17	Ndepth: A Randomized Controlled Trial of a Novel Dose-Prediction Equation to Determine Maximum Tolerated Dose for Hydroxyurea Therapy in Pediatric Patients with Sickle Cell Anemia. Blood, 2019, 134, 2267-2267.	1.4	3
18	Iron Unloading By Therapeutic Phlebotomy in Previously Transfused Children with Sickle Cell Anemia: The Twitch Experience. Blood, 2016, 128, 1018-1018.	1.4	3

#	Article	IF	Citations
19	Changes in Extrahepatic Iron Load in Response to Iron Chelation Versus Phlebotomy: Observations from the Twitch Trial. Blood, 2016, 128, 202-202.	1.4	3
20	Ndepth: Novel Dose Escalation to Predict Treatment with Hydroxyurea. Blood, 2015, 126, 3419-3419.	1.4	2
21	Safety and Efficacy of Dose-Escalation Hydroxyurea Therapy in Infants and Young Children: A Retrospective Cohort Study. Blood, 2018, 132, 3658-3658.	1.4	1
22	Comparison of Clinical Outcomes Between Adult and Pediatric Patients (pts) with Sickle Cell Disease (SCD): 3-Year (y) Follow-up in a Prospective, Longitudinal, Noninterventional Registry Trial. Blood, 2014, 124, 4890-4890.	1.4	1
23	Effects of Genetic Polymorphisms on Leukocyte and Neutrophil Counts and Maximum Tolerated Dose of Hydroxyurea in Children with Sickle Cell Anemia. Blood, 2015, 126, 2165-2165.	1.4	1
24	Safety and efficacy of doseâ€escalation hydroxyurea therapy in very young children with sickle cell anemia: A retrospective cohort study. Pediatric Blood and Cancer, 2020, 67, e28461.	1.5	0
25	Paper-Based Assay for Quantification of HbS in Blood of Sickle Cell Disease Patients. Blood, 2014, 124, 1371-1371.	1.4	0
26	Initial Clinical Validation of a Rapid, Low-Cost, Paper-Based Diagnostic Test for Sickle Cell Anemia As a Tool to Facilitate Newborn Screening in Resource-Limited Settings. Blood, 2015, 126, 979-979.	1.4	0
27	Blood Antioxidant Defenses and Sickle Cell Disease: Analyzing Cytochrome b Reductase 1 Protein Levels and Structure in Erythrocyte Membranes. Blood, 2015, 126, 2170-2170.	1.4	0